Log In
BCIQ
Print this Print this
 

P3378

  Manage Alerts
Collapse Summary General Information
Company National Research Council Canada
DescriptionPeptide that binds to tumor-associated human clusterin (CLU; APOJ)
Molecular Target Clusterin (CLU) (APOJ)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationCancer, Diagnostic
Indication DetailsIdentify cancer patients who would benefit the most from an anti-clusterin-based therapy and monitor treatment response; Imaging of solid tumors in vivo
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/14/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today